Therapeutic Effectiveness of Immunoradiotherapy on Brain-metastatic BRAF/MEK Inhibitor-resistant Melanoma with Balloon Cell Change

Goto, Hisao; Shimauchi, Takatoshi; Fukuchi, Kazuki; Yokota, Naoki; Koizumi, Shinichiro; Aoshima, Masahiro; Endo, Yuno; Masuda, Yurika; Miyazawa, Hidehiko; Kasuya, Akira; Nakamura, Katsumasa; Ito, Taisuke; Tokura, Y.

doi:10.2340/00015555-3134

Cited by 8 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, only four of the drugs used to treat colorectal cancer are related to genetic mutations, and biomarkers must be detected. The detection-based biomarkers for treatment include EGFR, MSI-H/dMMR, BRAF + MEK, and NTRK fusion targets[ 31 , 32 ]. These patients must have wild-type KRAS/NRAS/BRAF and only left-sided tumors after gene testing.…”

Section: Discussionmentioning

confidence: 99%

Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer

Yan¹,

Lin²,

Zhang³

et al. 2020

WJGO

View full text Add to dashboard Cite

BACKGROUND Kras mutant colon cancer shows abnormal activation of the nuclear factor kappa-B (NF-κB) pathway, resulting in the proliferation of tumor cells. Treatment with fluorouracil (5-FU) might not achieve the expected inhibition of proliferation of malignant cells based on the fluorouracil-induced activation of the NF-κB pathway. AIM To detect whether interleukin (IL)-1 receptor antagonist (IL-1RA) could increase the chemosensitivity to 5-FU by decreasing the activation of the NF-κB pathway and reducing the proliferation of colon cancer cells. METHODS Western blot analysis was performed to detect the persistent activation of the NF-κB pathway in colon cancer cell lines. Reverse transcription-polymerase chain reaction was used to detect the IL-1RA-reduced expression levels of IL-6, IL-8, IL-17, IL-21 and TLR4 in colon cancer cell lines. We used a xenograft nude mouse model to demonstrate the downregulation of the NF-κB pathway by blocking the NF-κB-regulated IL-1α feedforward loop, which could increase the efficacy of chemotherapeutic agents in inhibiting tumor cell growth. RESULTS IL-1 receptor antagonist could decrease the expression of IL-1α and IL-1β and downregulate the activity of the NF-κB pathway in Kras mutant colon cancer cells. Treatment with 5-FU combined with IL-1RA could increase the chemosensitivity of the SW620 cell line, and decreased expression of the TAK1/NF-κB and MEK pathways resulted in limited proliferation in the SW620 cell line. CONCLUSION Adjuvant chemotherapy with IL-1RA and 5-FU has a stronger effect than single chemotherapeutic drugs. IL-1RA combined with fluorouracil could be a potential neoadjuvant chemotherapy in the clinic.

show abstract

Section: Discussionmentioning

confidence: 99%

Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer

Yan¹,

Lin²,

Zhang³

et al. 2020

WJGO

View full text Add to dashboard Cite

show abstract

“…In recent years, some authors such as Chen Y. have described cases of BCM developing a mutation of BRAFV600E in the metastatic setting and, therefore, brought attention to how this entity, despite the peculiar morphological characteristics, is able to behave also from the molecular point of view as a conventional MM. This is already affecting the therapeutic side, as shown by recent papers [ 67 ].…”

Section: Discussionmentioning

confidence: 98%

Balloon Cell Melanoma: Presentation of Four Cases with a Comprehensive Review of the Literature

et al. 2022

View full text Add to dashboard Cite

Background: balloon cell melanoma represents less than 1% of all histological forms of malignant melanoma and represents a diagnostic challenge for the dermatopathologist. Methods: in this paper we present our cases of BCM found in our daily practice from 1 January 2008 to 31 December 2021, and we conduct a review of the literature relating to this entity in the period from the first description, 1970, to early 2022. Results: four cases of melanoma balloon cell have been extrapolated from our electronic database, while in the review of the literature we have identified 115 cases of patients with primary and/or metastatic BCM. Conclusions: we believe that future studies with numerous case series are essential not only to increase the knowledge of the pathophysiology of this neoplasm but also to correctly evaluate the response of BCM patients to new oncological therapies.

show abstract

“…8,9,51,62 Compared to ocular lesions, recent reports of neurological BCM cases are available, all with brain metastases. 15,19,30,34,42 Respiratory, gastrointestinal, and gynecological lesions were the rarest primary presentations.…”

Section: Discussionmentioning

confidence: 99%

Balloon cell melanoma: a systematic review

et al. 2021

View full text Add to dashboard Cite

Balloon cell melanoma (BCM) is a rare presentation of malignant melanoma characterized by large, foamy melanocytes lacking pigmentation. This is a comprehensive review of the clinical, dermoscopic, and histological features among BCM cases reported in the literature. A systematic review of all case reports and series published since 1970 was conducted via MEDLINE, Embase, and Web of Science, using "balloon cell melanoma" and synonymous search terms. Our systematic search identified 76 cases (49% male, 51% female) of BCM in the literature. The mean age at presentation was 57.81 years. Prior skin cancer, particularly melanoma (47%), accounted for 58% of pertinent medical history.Prominent clinical exam findings included raised (46%), ulcerated (73%) lesions larger than 1 cm (68%) in the lower extremities (35%). Median Breslow thickness of primary BCM cases was 2.5 mm. Hairpin vessels (75%) and structureless architecture (75%) were predominant on dermoscopy. Notable histopathology included large (47%), vacuolated (58%) cells with foamy cytoplasm (62%) and conspicuous nucleoli (27%). Positive S-100 immunohistochemistry (73%) was most frequently employed to diagnose BCM. We observed 47% primary and 53% metastatic BCM cases. Of metastatic BCMs, balloon cells in the primary lesion were unknown in 48%, devoid in 33%, and present in 20% of cases.All metastases displayed predominant balloon cell morphology. BCM may represent an advanced phase in the progression of malignant melanoma. Improved awareness of BCM characteristics among clinicians may reduce the risk of misdiagnoses.

show abstract

Therapeutic Effectiveness of Immunoradiotherapy on Brain-metastatic BRAF/MEK Inhibitor-resistant Melanoma with Balloon Cell Change

Cited by 8 publications

References 13 publications

Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer

Interleukin-1 receptor antagonist enhances chemosensitivity to fluorouracil in treatment of Kras mutant colon cancer

Balloon Cell Melanoma: Presentation of Four Cases with a Comprehensive Review of the Literature

Balloon cell melanoma: a systematic review

Contact Info

Product

Resources

About